181 related articles for article (PubMed ID: 18057188)
1. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.
Dale W; Basu A; Elstein A; Meltzer D
Med Decis Making; 2008; 28(1):102-12. PubMed ID: 18057188
[TBL] [Abstract][Full Text] [Related]
2. A linear index for predicting joint health-states utilities from single health-states utilities.
Basu A; Dale W; Elstein A; Meltzer D
Health Econ; 2009 Apr; 18(4):403-19. PubMed ID: 18773392
[TBL] [Abstract][Full Text] [Related]
3. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.
Dale W; Bilir SP; Hemmerich J; Basu A; Elstein A; Meltzer D
Med Care; 2011 Jan; 49(1):59-66. PubMed ID: 21150801
[TBL] [Abstract][Full Text] [Related]
4. Predicting utility for joint health states: a general framework and a new nonparametric estimator.
Bo Hu ; Fu AZ
Med Decis Making; 2010; 30(5):E29-39. PubMed ID: 20643911
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
6. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.
Elkin EB; Cowen ME; Cahill D; Steffel M; Kattan MW
Med Decis Making; 2004; 24(5):504-10. PubMed ID: 15358999
[TBL] [Abstract][Full Text] [Related]
7. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
9. Invariance and inconsistency in utility ratings.
Bravata DM; Nelson LM; Garber AM; Goldstein MK
Med Decis Making; 2005; 25(2):158-67. PubMed ID: 15800300
[TBL] [Abstract][Full Text] [Related]
10. Utilities for prostate cancer health states in men aged 60 and older.
Stewart ST; Lenert L; Bhatnagar V; Kaplan RM
Med Care; 2005 Apr; 43(4):347-55. PubMed ID: 15778638
[TBL] [Abstract][Full Text] [Related]
11. Implications of spillover effects within the family for medical cost-effectiveness analysis.
Basu A; Meltzer D
J Health Econ; 2005 Jul; 24(4):751-73. PubMed ID: 15960995
[TBL] [Abstract][Full Text] [Related]
12. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
Bleichrodt H
Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
[TBL] [Abstract][Full Text] [Related]
13. A new and more robust test of QALYs.
Doctor JN; Bleichrodt H; Miyamoto J; Temkin NR; Dikmen S
J Health Econ; 2004 Mar; 23(2):353-67. PubMed ID: 15019761
[TBL] [Abstract][Full Text] [Related]
14. Utilities should not be multiplied: evidence from the preference-based scores in the United States.
Fu AZ; Kattan MW
Med Care; 2008 Sep; 46(9):984-90. PubMed ID: 18725854
[TBL] [Abstract][Full Text] [Related]
15. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
16. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study.
Schmitt J; Meurer M; Klon M; Frick KD
Br J Dermatol; 2008 Feb; 158(2):351-9. PubMed ID: 18070214
[TBL] [Abstract][Full Text] [Related]
17. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
18. A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis.
Bleichrodt H; Doctor J; Stolk E
J Health Econ; 2005 Jul; 24(4):655-78. PubMed ID: 15960990
[TBL] [Abstract][Full Text] [Related]
19. Utility measures of health-related quality of life in patients treated for benign paroxysmal positional vertigo.
Roberts RA; Abrams H; Sembach MK; Lister JJ; Gans RE; Chisolm TH
Ear Hear; 2009 Jun; 30(3):369-76. PubMed ID: 19322083
[TBL] [Abstract][Full Text] [Related]
20. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: a decision analysis.
Neuman HB; Elkin EB; Guillem JG; Paty PB; Weiser MR; Wong WD; Temple LK
Dis Colon Rectum; 2009 May; 52(5):863-71. PubMed ID: 19502849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
